Compare PLSE & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | VCEL |
|---|---|---|
| Founded | 2014 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2015 | 1996 |
| Metric | PLSE | VCEL |
|---|---|---|
| Price | $24.74 | $34.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $22.00 | ★ $57.75 |
| AVG Volume (30 Days) | 347.1K | ★ 588.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | $840.00 | $19.40 |
| Revenue Next Year | $287.54 | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $12.56 | $28.95 |
| 52 Week High | $27.98 | $45.97 |
| Indicator | PLSE | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 56.18 | 49.86 |
| Support Level | $17.58 | $33.79 |
| Resistance Level | $27.14 | $34.77 |
| Average True Range (ATR) | 1.82 | 1.49 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 67.22 | 57.57 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.